Pancrelipase

Summary

Pancrelipase (CHEMBL2108074) is an approved enzyme; indicated across 7 conditions including chronic pancreatitis and exocrine pancreatic insufficiency.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Enzyme
• Indications: 7 conditions
• Clinical trials: 16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108074
Name	Pancrelipase
Type	Enzyme
Max phase	4

Also known as: Lipancreatin, Pancrelipase, Pertzye, PANCRELIPASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic pancreatitis	3	MONDO:0005003	EFO:0000342
exocrine pancreatic insufficiency	3	MONDO:0001684	MONDO:0001684
cystic fibrosis	3	MONDO:0009061	MONDO:0009061
pancreatitis	2	MONDO:0004982	EFO:0000278
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
hypoglycemia	1	MONDO:0004946	HP:0001943
type 1 diabetes mellitus	0	MONDO:0005147	MONDO:0005147

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE4	6
PHASE2	4
Not specified	4
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06477159	PHASE4	RECRUITING	Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency
NCT00744250	PHASE4	TERMINATED	Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control
NCT01641341	PHASE4	COMPLETED	Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
NCT02475369	PHASE4	TERMINATED	Pancreatic Enzyme Supplementation for Celiac Disease
NCT03859869	PHASE4	TERMINATED	A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)
NCT03924947	PHASE4	COMPLETED	A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
NCT04098237	PHASE2	ACTIVE_NOT_RECRUITING	Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency
NCT05642962	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
NCT00217204	PHASE2	COMPLETED	An Effectiveness, Safety, and Palatability Study of Pancrelipase Microtablets in Infants and Toddlers With Cystic Fibrosis and Fat Malabsorption
NCT02706236	PHASE2	WITHDRAWN	Trial of Pancreatic Enzyme Supplements (Pancrelipase) for Treating Pain in Patients With Chronic Pancreatitis
NCT02985801	PHASE1/PHASE2	TERMINATED	PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer
NCT03469258	PHASE2	TERMINATED	Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma
NCT00749099	Not specified	TERMINATED	Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum)
NCT01427712	Not specified	COMPLETED	Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
NCT01652157	Not specified	TERMINATED	Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
NCT02372383	Not specified	COMPLETED	Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).